Left Ventricular Assist Device Infections and the Potential Role for Dalbavancin: A Case Report | Zendy

Jessica HowardAnderson | Zendy; Stephanie M. Pouch | Zendy; Mary Elizabeth Sexton | Zendy; Aneesh K. Mehta | Zendy; Andrew L. Smith | Zendy; George M. Lyon | Zendy; Rachel FriedmanMoraco | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Left Ventricular Assist Device Infections and the Potential Role for Dalbavancin: A Case Report

Author(s) -

Jessica HowardAnderson,

Stephanie M. Pouch,

Mary Elizabeth Sexton,

Aneesh K. Mehta,

Andrew L. Smith,

George M. Lyon,

Rachel FriedmanMoraco

Publication year - 2019

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofz235

Subject(s) - dalbavancin , medicine , dosing , antibiotics , intensive care medicine , vancomycin , staphylococcus aureus , microbiology and biotechnology , biology , bacteria , genetics

Left ventricular assist device infections (LVADIs) are common but challenging to treat, often requiring prolonged courses of intravenous antibiotics. Dalbavancin could have a role in treating patients with chronic LVADIs given its less frequent dosing requirements. Here, we illustrate a case in which dalbavancin was used as suppressive therapy for an LVADI for greater than 7 months.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research